Literature DB >> 1143090

Metabolism of 3-methylhistidine in man.

C L Long, L N Haverberg, V R Young, J M Kinney, H N Munro, J W Geiger.   

Abstract

The metabolism of L-3-methylhistidine was studied in man using intravenously administered ((14)C)3-methylhistidine. Analysis for expired (14)CO2 for periods up to 2 hr following a single intravenous injection revealed no radioactivity, indicating that this compound is not oxidized in man. Analysis of urine samples for total radioactivity showed that 75% of the administered dose was excreted in 24 hr and 95% in 48 hr. Ion-exchange chromatography of urine samples with monitoring of the column eluated by a flow liquid-scintillation technique showed the presence of only two radioactive peaks. The time taken to elute these peaks was compatible with the major excretory component (95.5%) being ((14)C)3-methylhistidine, accompanied by a small amount (4.5%) in the form of N-acetyl-((14)C)3-methylhistidine. The plasma disappearance curves of ((14)C)3-methylhistidine suggested a half-life of approximately 130 min. The inability ot oxidize 3-methylhistidine and its quantitative excretion as the original compound as well as its N-acetyl derivative is similar to its metabolic fate in the rat and therefore suggests that 3-methylhistidine excretion may provide a reliable measure of actin and myosin turnover in the whole animal or in human subjects.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1143090     DOI: 10.1016/0026-0495(75)90084-0

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  37 in total

1.  Genetic studies on the muscle protein turnover rate of coturnix quail.

Authors:  Y Maeda; K Hayashi; T Hashiguchi; S Okamoto
Journal:  Biochem Genet       Date:  1986-04       Impact factor: 1.890

2.  Urinary zinc excretion in Crohn's disease.

Authors:  L Pironi; M Miglioli; G L Cornia; M A Ursitti; M Tolomelli; S Piazzi; L Barbara
Journal:  Dig Dis Sci       Date:  1987-04       Impact factor: 3.199

3.  Tight Glycemic Control With Insulin Does Not Affect Skeletal Muscle Degradation During the Early Postoperative Period Following Pediatric Cardiac Surgery.

Authors:  Jeremy G Fisher; Eric A Sparks; Faraz A Khan; Jamin L Alexander; Lisa A Asaro; David Wypij; Michael Gaies; Biren P Modi; Christopher Duggan; Michael S D Agus; Yong-Ming Yu; Tom Jaksic
Journal:  Pediatr Crit Care Med       Date:  2015-07       Impact factor: 3.624

4.  Clinical usefulness of urinary 3-methylhistidine excretion in indicating muscle protein breakdown.

Authors:  M Elia; A Carter; S Bacon; C G Winearls; R Smith
Journal:  Br Med J (Clin Res Ed)       Date:  1981-01-31

5.  [Changes in anthropometrical, laboratory-chemical and immunological indices as functions of anabolism and catabolism. Definition of nutritional status].

Authors:  J Mörsdorf; H Gofferje; K Schultis
Journal:  Z Ernahrungswiss       Date:  1982-06

6.  Quantitative importance of non-skeletal-muscle sources of N tau-methylhistidine in urine.

Authors:  D J Millward; P C Bates; G K Grimble; J G Brown; M Nathan; M J Rennie
Journal:  Biochem J       Date:  1980-07-15       Impact factor: 3.857

7.  Increased myofibrillar protein catabolism in Duchenne muscular dystrophy measured by 3-methylhistidine excretion in the urine.

Authors:  R O McKeran; D Halliday; P Purkiss
Journal:  J Neurol Neurosurg Psychiatry       Date:  1977-10       Impact factor: 10.154

8.  The metabolic effects of moderately severe upper gastrointestinal haemorrhage in man.

Authors:  K J Foster; K G Alberti; C Binder; G Holdstock; S J Karran; C L Smith; S Talbot; D C Turnell
Journal:  Postgrad Med J       Date:  1982-01       Impact factor: 2.401

9.  Decrease in urinary excretion of 3-methylhistidine by patients with Duchenne muscular dystrophy during glucocorticoid treatment.

Authors:  H Kawai; K Adachi; Y Nishida; T Inui; C Kimura; S Saito
Journal:  J Neurol       Date:  1993       Impact factor: 4.849

Review 10.  Dietary protein and blood pressure: a systematic review.

Authors:  Wieke Altorf-van der Kuil; Mariëlle F Engberink; Elizabeth J Brink; Marleen A van Baak; Stephan J L Bakker; Gerjan Navis; Pieter van 't Veer; Johanna M Geleijnse
Journal:  PLoS One       Date:  2010-08-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.